← Back to Clinical Trials
Recruiting Phase 4 NCT07034677

Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism

Trial Parameters

Condition Hypoparathyroidism Post-surgical
Sponsor Lars Rejnmark
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 24
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-08
Completion 2025-12
Interventions
Indapamide 1.5 MG SRPlacebo

Brief Summary

The aim of this study is to investigate the effect of daily treatment with Indapamide for 14 days on urinary calcium excretion in patients with post surgical hypoparathyroidisme.

Eligibility Criteria

Inclusion Criteria: 1. Chronic post surgical hypoparathyroidism diagnosed \> 1 year ago 2. Age ≥ 18 years 3. Require treatment with active vitamin D ≥ 1 µg/day 4. Ionized plasma calcium between 1.15-1.25 mmol/L 5. 25(OH)D vitamin ≥ 50 nmol/L 6. Plasma magnesium \> 0.65 mmol/L 7. Able to read and understand Danish 8. Willing and able to sign the informed consent form Exclusion Criteria: 1. Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m3 2. Active cancer or former (except thyroid and basal cell skin) cancer treatment \< 1 year ago 3. Pregnancy, pregnancy plans, or breastfeeding \< 1 year ago 4. Abnormal arterial pressure at time of screening defined as symptomatic hypotension or systolic blood pressure \< 100 mmHg 5. Plasma potassium \< 3.5 mmol/L 6. Any current disease that might affect the calcium metabolism such as but not limited to: 1. Recent prolonged immobility 2. Untreated diabetes (HbA1c \> 53 mmol/mol) 3. Severe liver disease or hepatic encephalopathy 4. Untrea

Related Trials